Imagine a treatment that could offer a glimmer of hope to patients battling high-risk blood cancers, achieving a staggering 91% response rate. That's exactly what a groundbreaking study has revealed for those with high-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). But here's where it gets even more compelling: this success comes from combining two existing drugs, oral decitabine/cedazuridine (Inqovi) and venetoclax (Venclexta), in a way that not only boosts response rates but also extends survival times significantly.
In a phase 1/2 clinical trial (NCT04655755) presented at the 2025 ASH Annual Meeting, researchers reported that 69 patients treated with this combination achieved an overall response rate (ORR) of 91%, as per the International Working Group (IWG) 2006 criteria. And this is the part most people miss: within this impressive response, 45% of patients achieved complete remission (CR), and 46% reached marrow CR (mCR). What’s more, these responses were swift, with most patients showing improvement within just one treatment cycle. The median overall survival (OS) was a remarkable 30 months, with 68.8% of patients alive at one year and 40.7% at three years.
But here's where it gets controversial: while the results are undeniably promising, the treatment isn’t without challenges. Grade 3 or higher adverse effects were reported in 78% of patients, with cytopenias—particularly anemia, thrombocytopenia, and neutropenia—being the most common. Infectious complications, including sepsis and pneumonia, were also significant concerns. Lead researcher Alex Bataller, MD, PhD, emphasized the critical need for infection prophylaxis and dose adjustments to manage these risks. Yet, despite these challenges, 38 patients were able to proceed to hematopoietic stem cell transplantation (HSCT), a potentially curative step, with encouraging survival rates post-transplant.
The trial’s design was meticulous, starting with a dose-escalation phase to determine the safest and most effective dosing. Phase 1 evaluated two dose levels, with the higher dose (decitabine/cedazuridine 35 mg/100 mg for 5 days plus venetoclax 400 mg for 14 days) declared the recommended phase 2 dose (RP2D) due to its tolerability. Phase 2 then confirmed the efficacy of this regimen in a larger cohort of 60 patients.
The study population was diverse, with a median age of 71 and a majority of male participants. Most patients had HR-MDS, with a significant portion classified as very high risk according to the International Prognostic Staging System (IPSS-R). Here’s a thought-provoking question: Could this combination become the new standard of care for these high-risk patients, or will the toxicity profile limit its widespread adoption? Weigh in below—your perspective could spark a vital discussion.
In conclusion, this trial not only highlights the potential of combining decitabine/cedazuridine with venetoclax but also underscores the delicate balance between efficacy and safety in cancer treatment. As we await further research, one thing is clear: this approach has the potential to change the landscape for patients with HR-MDS and CMML. What do you think? Is this a game-changer, or are the risks too high?
